Prostate Cancer Therapeutics Market Segments and Forecasts Up to 2023 Research Reports-Transparency Market Research

Prostate Cancer Therapeutics Market - Global

Industry Analysis, Size, Share, Growth, Trends Single User

and Forecast 2015 - 2023

USD 4315.5









Transparency Market Research

State Tower,

90, State Street, Suite 700.

Albany, NY 12207

United States

www.transparencymarketresearch.com

sales@transparencymarketresearch.com

License:

Flat 10% Discount!!

Free Customization as per your requirement

You will get Custom Report at Syndicated Report

price

Report will be delivered with in 15-20 working days

Request Sample

Buy Now

REPORT DESCRIPTION

Prostate cancer is among serious health issue among men has large socioeconomic impact on the society. It is the most common cancer

diagnosed among men in developed regions, while it is sixth most common cancer diagnosed in less developed nations. Routine screening, early

diagnosis, and recent treatment options have enabled increased survival of prostate cancer patients. Prostate cancer is an abnormal and

uncontrolled growth of cells in prostate gland of a male individual. Approximately 75% of prostate cancers are developed sporadically in which

genetic changes occur after birth. Although, cause prostate cancer is largely unknown, some of the prime factors associated with the disease

include obesity, overweight and past history of certain cancers. A person with cardiovascular disease is more prone to advanced metastatic

cancer.

Browse Full Report With TOC:- http://www.transparencymarketresearch.com/prostate-cancer-therapeutics-market.html

Androgens have significant role in the pathogenesis of prostate cancer and therefore androgen-deprivation therapy (ADT) was found to be most

useful in treating of locally advanced or metastatic prostate cancer. Presently, the prostate cancer therapeutics market is driven by major drugs

such as Zytiga (Johnson & Johnson), Xtandi (Astellas Pharma, Inc. / Medivation, Inc.), Provenge (Dendreon Corporation), Jevtana (Sanofi) and

Xofigo (Bayer Healthcare...